Brian J Yoder

Summary

Publications

  1. ncbi The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study
    Sarah M Short
    Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
    Breast J 13:130-9. 2007
  2. ncbi The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
    David G Hicks
    Clarient Inc, Aliso Veijo, California, USA
    BMC Cancer 10:108. 2010
  3. ncbi Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast
    Brian J Yoder
    Department of Pathology, University of Florida, Gainesville, Florida 33805, USA
    Breast J 13:172-9. 2007
  4. ncbi Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk
    Brian J Yoder
    Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Am J Surg Pathol 32:765-72. 2008
  5. ncbi Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery-Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
  6. ncbi Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR
    David G Hicks
    Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Surg Pathol 30:1097-104. 2006
  7. ncbi Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Brian Z Ring
    Applied Genomics Inc, 863 Mitten Rd #103, Burlingame, CA, USA
    J Clin Oncol 24:3039-47. 2006
  8. ncbi The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
    Erinn Downs-Kelly
    Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Surg Pathol 29:1221-7. 2005
  9. ncbi The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study
    David G Hicks
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 36:348-56. 2005
  10. ncbi The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course
    Brian J Yoder
    Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 11:186-92. 2005

Collaborators

  • Irina Rufforny
  • David G Hicks
  • Joseph P Crowe
  • R R Tubbs
  • Robert J Weil
  • Danny R Welch
  • Erinn Downs-Kelly
  • Sarah M Short
  • Shannon M Tarr
  • Brian Z Ring
  • James D Pettay
  • Kara A Coleman
  • Toni K Choueiri
  • Nichole L Prescott
  • Simas Laniauskas
  • Thomas G Budd
  • Erinn Downs Kelly
  • Douglas T Ross
  • Robert S Seitz
  • Rod Beck
  • William J Shasteen
  • Torsten O Nielsen
  • G Thomas Budd
  • Maggie C U Cheang
  • Noel C Estopinal
  • Thomas Grogan
  • Marek Skacel
  • Mark Stoler
  • Patrick Roche

Detail Information

Publications10

  1. ncbi The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study
    Sarah M Short
    Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
    Breast J 13:130-9. 2007
    ..Further study of a role for paxillin expression in predicting response to cytotoxic regimens or targeted treatments is warranted...
  2. ncbi The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
    David G Hicks
    Clarient Inc, Aliso Veijo, California, USA
    BMC Cancer 10:108. 2010
    ..Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients...
  3. ncbi Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast
    Brian J Yoder
    Department of Pathology, University of Florida, Gainesville, Florida 33805, USA
    Breast J 13:172-9. 2007
    ..The goal of this review is to present what is currently known about the molecular profiles of infiltrating ductal and lobular carcinoma and how they relate to conventional histopathology and biologic behavior...
  4. ncbi Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk
    Brian J Yoder
    Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Am J Surg Pathol 32:765-72. 2008
    ..The 3 most important features of stage IA tumors in predicting tumor recurrence were the depth of invasion, presence of SCC at the surgical margins, and the histologic grade...
  5. ncbi Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery-Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
    ..BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors...
  6. ncbi Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR
    David G Hicks
    Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Surg Pathol 30:1097-104. 2006
    ....
  7. ncbi Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Brian Z Ring
    Applied Genomics Inc, 863 Mitten Rd #103, Burlingame, CA, USA
    J Clin Oncol 24:3039-47. 2006
    ..CONCLUSION: A panel of five antibodies can significantly improve on traditional prognosticators in predicting outcome for ER-positive breast cancer patients...
  8. ncbi The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
    Erinn Downs-Kelly
    Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Surg Pathol 29:1221-7. 2005
    ..These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma...
  9. ncbi The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study
    David G Hicks
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 36:348-56. 2005
    ..If TOP2A gene dosage can be confirmed to correlate with tumor responsiveness to anthracycline-based therapy in the clinical setting, FISH testing for TOP2A status may be warranted to aid in the selection of the most appropriate therapy...
  10. ncbi The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course
    Brian J Yoder
    Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 11:186-92. 2005
    ..If so, then fascin may represent a new molecular target for therapeutic intervention in patients with ER-negative breast cancer...